Watch the video and download the slides.


Overview of safety considerations for next-generation androgen receptor inhibitors for nmCRPC: The role of the nurse

GU NURSES CONNECT expert Jennifer Sutton provides an overview of safety considerations for next-generation androgen receptor inhibitors for non-metastatic castration-resistant prostate cancer and the role of the nurse.

Watch the video and download the slides.

Hi I’m Jennifer Sutton and I’m the Director of Nursing and Administration at Carolina Urologic Research Centre in Myrtle Beach, South Carolina.

On behalf of GU Nurses CONNECT I’m going to review safety considerations for next- generation androgen receptor inhibitors, for non-metastatic castration-resistant prostate cancer (nmCRPC) and the role of the nurse.

Non-metastatic CRPC is the earliest form of castration disease and these patients are at significant risk for developing metastatic disease which carries a poor prognosis with shorter overall survival and reduced health-related quality of life.

Non-metastatic CRPC patients are mostly asymptomatic from their disease, so treatment should delay development of metastases as well as maintaining quality of life.

Next-generation oral androgen receptor inhibitors

Since 2018 the treatment landscape of non-metastatic CRPC has changed with the approval of three next-generation oral androgen receptor (AR) inhibitors. These are apalutamide, enzalutamide and darolutamide.

With the availability of new AR targeted options, oncology nurses play a crucial role in the decision-making process, educating and supporting patients with non-metastatic castration-resistant prostate cancer and managing their disease, and ensuring that they receive the most appropriate treatment.

Balancing treatment efficacy against the potential risk of treatment-emergent adverse events is an important clinical consideration. There are eight common treatment-emergent adverse events that nurses should be aware of and these are: fatigue; bone health; cognitive impairment; rash; metabolic changes; cardiovascular changes (including hypertension); hot flashes and sexual health.

While no head-to-head comparisons of apalutamide, enzalutamide and darolutamide have been conducted to date all three have demonstrated comparable efficacy and maintaining quality of life in the SPARTAN, PROSPER and ARAMIS trials.

Since non-metastatic CRPC patients are largely asymptomatic, therapeutic benefits should be balanced against the potential risk of adverse events. Oncology nurses can make a major contribution to successful therapeutic outcomes by educating patients with non-metastatic CRPC on their disease and available treatment options, recognising and managing specific treatment-emergent adverse events and modifying treatment decisions accordingly.

Please take a look at the prepared slides and on behalf of GU Nurses CONNECT thank you for listening and I hope you find this relevant to your practice.

Jennifer Sutton is a registered nurse and the Director of Nursing and Administration at Carolina Urologic Research Center in Myrtle Beach, SC.  After receiving her Bachelor of Science degree in Exercise Science with a minor in Chemistry from the University of South Carolina, she earned her Associate Degree in Nursing from Horry Georgetown Technical College. Jennifer is a member of the Society of Urologic Nurses and Associates, the Oncology Nursing Society, and the Association of Clinical Research Professionals (ACRP).   She is an ACRP-certified Clinical Research Coordinator and has more than 11 years of experience managing and administering cutting edge therapies to patients with genitourinary malignancies and other urologic disorders.  Additionally, she manages a team of research professionals that coordinate phase I-IV clinical trials in all areas of urology.  In recent years, she has served on multiple prostate cancer and bladder cancer advisory boards and has published articles on emerging prostate cancer treatments and effective structuring and management of a clinical research center. 

Jennifer Sutton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Janssen, Merck, Myovant and SeSen Bio. 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
Highlights from ASCO 2025

Coming Soon: Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Dr Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • clock 1 MIN
  • calendar May 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED
symposium Symposium
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer

Experts
Prof. Wolfgang Janni, Prof. Sherko Kümmel, Prof. Michail Ignatiadis
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Serie de podcasturi referitoare la gestionarea trombozei

Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului 

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis, Prof. Jerzy Windyga, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar May 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
video Video
Oncology Hemato-oncology 
Optimising the sequence of novel therapies from early relapse in multiple myeloma

Improving the survival of patients with relapsed/refractory multiple myeloma

Experts
Prof. Hermann Einsele, Prof. Evangelos Terpos
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
podcast Podcast
Oncology 
Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC)

Chemotherapy strategies that matter

Experts
Prof. Shubham Pant, Prof. Efrat Dotan
Endorsed by
DiCE ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Ipsen USA